Doximity (NYSE: DOCS) capped off one of its strongest trading weeks in recent memory on Friday, with shares closing at $27.40, a 32.6% gain for the session and approximately 31% for the week. The surge followed the release of the company's fiscal first-quarter results, which prompted investors to embrace the clinical AI strategy even as management acknowledged that new AI products have yet to contribute meaningful reported revenue.
The market's reaction highlighted an unusual disconnect. While investors rewarded the potential for future AI monetization, the latest guidance pointed to lower near-term profitability. This divergence makes execution over the next two quarters far more critical than the earnings beat itself.
AI Revenue: The Missing Piece
The central question for investors is whether AI revenue can arrive quickly enough to justify higher spending. Management stated that no AI Search revenue was recognized in the June quarter because deployments are still ramping. However, they expect most contracted AI Search revenue to begin flowing in the fiscal third quarter.
Despite the absence of AI revenue, usage metrics are encouraging. CEO Jeff Tangney reported strong physician engagement across AI products, with AI Search query volume increasing more than 25% sequentially and AI Scribe users growing roughly tenfold year over year. These metrics, however, have not yet translated into reported AI Search revenue, explaining why investors focused as much on guidance as on quarterly results.
Quarterly Performance and Guidance
Fiscal Q1 results were solid, although not flawless. Revenue came in at $156.6 million, up 7% year over year and above Wall Street expectations. Adjusted EBITDA was $74.8 million, down from $79.8 million a year earlier, and non-GAAP diluted EPS of $0.29 slightly missed some analyst forecasts. Free cash flow also declined to $39.6 million from $60.1 million.
Looking ahead, Doximity raised its fiscal 2027 revenue outlook to $671M–$681M from $664M–$676M, but lowered its adjusted EBITDA guidance to $309M–$329M from $323M–$335M. The revenue midpoint increased by only $6 million, while the EBITDA midpoint fell by $10 million, reflecting increased AI investment.
Analyst Reactions and Valuation
Wall Street generally welcomed the strategic direction, though opinions remain divided on valuation after Friday's rally. Piper Sandler maintained an Overweight rating with a $47 target, Needham & Company kept a Buy with a $41 target, and Evercore set an In Line rating with a $40 target. Raymond James Financial has an Outperform rating with a $38 target, while JPMorgan Chase is Neutral with a $31 target. BMO Capital Markets rates it Market Perform with a $30 target, and Bank of America is Underperform with a $20 target.
The stock's intraday high of $40.00 on Friday was 31.5% above the closing price, indicating significant volatility. With a market cap of $4.93 billion and a P/E ratio of 32.49, the stock trades at a premium that may already reflect high expectations for AI-driven growth.
Financial Flexibility and Risks
Doximity enters the second half with financial flexibility. The company remains debt-free, ended the quarter with a substantial cash and marketable securities position, and continues to repurchase shares. This provides a buffer while AI investments ramp up.
However, risks remain. The AI strategy depends on successful commercial rollout. Revenue guidance increased only modestly, while profitability guidance moved lower due to higher AI spending. If enterprise adoption or physician usage converts into revenue more slowly than management expects, investor enthusiasm could fade. Conversely, faster AI monetization or stronger healthcare marketing demand would represent the main upside risks.
Next week is unlikely to bring another company catalyst after earnings. Investors will instead watch for additional analyst revisions, while broader U.S. inflation and retail sales data may influence software valuations across the market. The coming quarters will be pivotal in determining whether Doximity can translate its AI promise into tangible financial results.
